Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;4(2):103-17.
doi: 10.1177/2040620712468289.

Management of imatinib-resistant patients with chronic myeloid leukemia

Pavan Kumar Bhamidipati  1 , Hagop Kantarjian, Jorge Cortes, A Megan Cornelison, Elias Jabbour
Affiliations

Management of imatinib-resistant patients with chronic myeloid leukemia

Pavan Kumar Bhamidipati et al. Ther Adv Hematol. 2013 Apr.

Abstract

Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

Keywords: CML; imatinib resistance; treatment; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alvarado Y., Kantarjian H., O’Brien S., Faderl S., Borthakur G., Burger J., et al. (2009) Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115: 3709–3718 - PMC - PubMed
    1. Baccarani M., Cortes J., Pane F., Niederwieser D., Saglio G., Apperley J., et al. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041–6051 - PMC - PubMed
    1. Baccarani M., Dreyling M. (2009) Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl. 4): 105–107 - PubMed
    1. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809–1820 - PubMed
    1. Bixby D., Talpaz M. (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program 461–476 - PubMed

LinkOut - more resources